- Home » News and EventsPage 5
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Completes Acquisition of Cell Therapy Manufacturing Facility from Bone Therapeutics
Nov 16, 2020
Catalent has completed the acquisition of Bone Therapeutics’ cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including all of its assets located in Gosselies, Belgium.
Taysha Gene Therapies Bolsters Manufacturing Capacity Through Partnership with Catalent
Nov 5, 2020
Taysha Gene Therapies and Catalent today announced a partnership to support the development and manufacturing of Taysha’s gene therapies at Catalent’s Maryland-based gene therapy facilities.
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®
Oct 22, 2020
Catalent and BrainStorm Cell Therapeutics Inc announced an agreement for the manufacture of NurOwn®, BrainStorm’s autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neuron disease.
Catalent to Discuss Innovative Approaches to Achieving T-Cell Commercial Readiness at Upcoming Industry Conference
Oct 12, 2020
Catalent today announced that Jesse Trekker, Ph.D., Business Director, Strategic Partnerships, Catalent Cell & Gene Therapy, will present at the Allogeneic Cell Therapies Summit, which will take place virtually on 26 – 28 October, 2020.
Innovation in Oncology, Cell & Gene Technology, and Post-COVID-19 Pharma Outlook to be Discussed by Catalent at CPhI
Oct 6, 2020
Catalent today announced that it will be participating in several roundtables alongside other leading industry experts at the CPhI Festival of Pharma, which is taking place virtually between Oct. 5 – 16, 2020.
Catalent Acquires New Biologics Facility to Create North American Clinical Manufacturing Center of Excellence
Sep 24, 2020
Catalent today announced that it has acquired a new manufacturing facility in Bloomington, Indiana, to create a North American center of excellence for early-phase clinical biologics formulation development and drug product fill/finish services.
Advantages of Oncolytic Viruses as Immunotherapies to be Discussed by Catalent Gene Therapy Expert at World Vaccine Congress
Sep 22, 2020
Catalent today announced that George Buchman, Ph.D., Vice President, Preclinical & Process Development, will present at the World Vaccine Congress, which will take place virtually on Sept. 28 – October 1, 2020.
T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy
Sep 21, 2020
T-knife and Catalent today announced they have signed an agreement to provide technology transfer and CGMP clinical manufacturing of T-knife’s T1367 T-cell receptor (TCR) program.
Catalent Biologics and Humanigen to Present a Case Study on Accelerated Scale Up of a Monoclonal Antibody to Treat COVID-19 at BioProcess International Conference
Sep 16, 2020
Catalent today announced that it will present at the upcoming BioProcess International virtual conference, taking place between Sept. 21 – 25, 2020.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.